Ogivri 150 mg Lyophilised powder for concentrate for solution for infusion
PDF Leaflet Revision Date: 09 September 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HER2 positive metastatic breast cancer and gastric adenocarcinoma.
Dosage (summary)
Loading dose: 4 mg/kg IV over 90 mins; Subsequent: 2 mg/kg weekly or 6 mg/kg every 3 weeks.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation due to potential fetal harm.
Key Drug Interactions
- Increased risk of cardiac dysfunction with anthracyclines post-treatment
Contraindications
- Hypersensitivity to trastuzumab
- Severe dyspnoea at rest
- Pregnancy and lactation
Common side effects
- Infusion-related symptoms
- Nausea
- Vomiting
- Fatigue
- Neutropenia
Counselling Points
- Monitor for infusion reactions
- Report any signs of cardiac dysfunction
- Avoid use in children under 18
Serious warnings
- Cardiomyopathy
- Severe hypersensitivity reactions
- Pulmonary events
Important Disclaimer
The Ogivri 150 mg Lyophilised powder for concentrate for solution for infusion professional information leaflet below is the property of Imperial Market Access South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
